BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 22328018)

  • 1. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P; Higano CS
    Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.
    Kittai A; Meshikhes M; Aragon-Ching JB
    Cancer Biol Ther; 2014 Oct; 15(10):1299-300. PubMed ID: 25046606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer targeting vaccines: surrogate measures of activity.
    Nemunaitis J
    Hum Vaccin Immunother; 2013 Jan; 9(1):213-8. PubMed ID: 23442594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
    Comiskey MC; Dallos MC; Drake CG
    Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.